Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Mabwell, WuXi XDC Collaborate to Accelerate ADC Projects | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Mabwell, WuXi XDC Collaborate to Accelerate ADC Projects

Long-term strategic collaboration aims to advance Mabwell's multiple adaptive ADC projects.

By: Anthony Vecchione

Mabwell, a biopharmaceutical company, and WuXi XDC, a global contract research, development, and manufacturing organization (CRDMO), signed a letter of intent (LOI) for long-term strategic collaboration on Mabwell’s multiple adaptive antibody–drug conjugates (ADC) projects.

Mabwell has had multiple products in clinical studies or preclinical research using its ADC technology platforms and CMC development capabilities.

In a statement, WuXi XDC said that it will make further efforts to accelerate global layout of Mabwell’s R&D and commercialization, cost reduction and R&D efficiency improvement by their leading antibody-drug conjugate production technology platform and integration capabilities.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics